October 22, 2018 by Chain Drug Review
Dupixent (dupilumab), eosinophilic phenotype or with oral corticosteroid-dependent asthma, George Yancopoulos, Olivier Brandicourt, Regeneron, Sanofi
Pharmacy, Supplier News
TARRYTOWN, N.Y. and PARIS — Regeneron Pharmaceuticals, Inc. and Sanofi today announced the U.S. Food and Drug Administration has approved Dupixent (dupilumab) as an add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. Dupixent inhibits the overactive signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13),
January 22, 2018 by Chain Drug Review
Alprolix, Bioverativ, Eloctate, hemophilia treatment market, John Cox, Olivier Brandicourt, Sanofi
Business, Pharmacy, Supplier News
PARIS — Sanofi plans to buy biopharmaceutical company Bioverativ Inc. in a deal valued at $11.6 billion. Waltham, Mass.-based Bioverativ specializes in therapies for hemophilia and other rare blood disorders. Sanofi said Monday that the addition of Bioverativ will boost its presence in specialty care and leadership in rare diseases as well as provide an expansion platform
October 16, 2017 by Chain Drug Review
Amgen, James Robinson, Joaquin Duato, Joseph Jimenez, Olivier Brandicourt, Pharmaceutical Research and Manufacturers of America, PhRMA, Robert Bradway, Stephen Ubl
Pharmacy, Supplier News
WASHINGTON — Pharmaceutical Research and Manufacturers of America (PhRMA) has named Amgen Inc. chairman and chief executive officer Robert Bradway as chairman-elect. Bradway will succeed Joaquin Duato, executive vice president and worldwide chairman of pharmaceuticals at Johnson & Johnson, as PhRMA chairman in February 2018. Previously, Bradway served as board treasurer for PhRMA. Sanofi CEO
October 3, 2016 by Chain Drug Review
Alan Main, Bayer, Boehringer Ingelheim, consumer health care, Olivier Brandicourt, Sanofi
Business, Pharmacy, Supplier News
PARIS — Sanofi has appointed former Bayer executive Alan Main as executive vice president of its newly formed Consumer HealthCare global business unit. Sanofi said Friday that Main, who also joins its executive committee, will be responsible for building and maintaining the company’s position in the consumer health care market, including the expected integration of
December 15, 2015 by Chain Drug Review
Andreas Barner, animal health, Boehringer Ingelheim, consumer health care, Olivier Brandicourt, Sanofi
Leading Headlines, Pharmacy, Supplier News
NEW YORK — Sanofi and Boehringer Ingelheim are in talks to swap their animal health and consumer health care businesses, respectively. The companies said Tuesday that the proposed transaction would involve an exchange of Sanofi’s Merial animal health business (“Merial”), valued at €11.4 billion ($12.45 billion U.S.), and Boehringer Ingelheim’s consumer health care business,valued at €6.7 billion ($7.32 billion U.S.).
September 1, 2015 by Chain Drug Review
Andy Conrad, diabetes care, Google, John Brooks, Joslin Diabetes Center, Olivier Brandicourt, Pascale Witz, Sanofi
Pharmacy, Supplier News
PARIS and MOUNTAIN VIEW, Calif. — Sanofi and the life sciences team at Google have formed a collaboration to improve care and outcomes for people with type 1 and type 2 diabetes. The companies said the alliance will pair Sanofi’s leadership in diabetes treatments and devices with Google’s expertise in analytics, miniaturized electronics and low-power chip